How to buy Forma Therapeutics stock | $18.09

Forma Therapeutics Holdings Inc is a biotechnology business based in the US. Forma Therapeutics shares (FMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Forma Therapeutics employs 139 staff and has a trailing 12-month revenue of around 0.00.

Forma Therapeutics stock price (NASDAQ: FMTX)

Use our graph to track the performance of FMTX stocks over time.

Forma Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-10.

Latest market close	$18.09
52-week range	$18.57 - $52.75
50-day moving average	$23.29
200-day moving average	$25.20
Wall St. target price	$56.29
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.05

Buy Forma Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Forma Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Forma Therapeutics price performance over time

Historical closes compared with the close of $18.09 from 2021-10-15

1 week (2021-10-08)	-3.42%
1 month (2021-09-17)	-23.70%
3 months (2021-07-16)	-23.18%
6 months (2021-04-16)	-29.47%

1 year (2020-10-16)	-63.79%
2 years (2019-10-13)	N/A
3 years (2018-10-13)	N/A
5 years (2016-10-13)	N/A

Forma Therapeutics financials

Revenue TTM	$7.4 million
Gross profit TTM	$-93,367,000
Return on assets TTM	-16.81%
Return on equity TTM	-26.67%
Profit margin	0%
Book value	$12.24
Market capitalisation	$934.5 million

TTM: trailing 12 months

Shorting Forma Therapeutics shares

There are currently 2.8 million Forma Therapeutics shares held short by investors – that's known as Forma Therapeutics's "short interest". This figure is 8.5% down from 3.1 million last month.

There are a few different ways that this level of interest in shorting Forma Therapeutics shares can be evaluated.

Forma Therapeutics's "short interest ratio" (SIR)

Forma Therapeutics's "short interest ratio" (SIR) is the quantity of Forma Therapeutics shares currently shorted divided by the average quantity of Forma Therapeutics shares traded daily (recently around 247207.10526316). Forma Therapeutics's SIR currently stands at 11.4. In other words for every 100,000 Forma Therapeutics shares traded daily on the market, roughly 11400 shares are currently held short.

However Forma Therapeutics's short interest can also be evaluated against the total number of Forma Therapeutics shares, or, against the total number of tradable Forma Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Forma Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Forma Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.121% of the tradable shares (for every 100,000 tradable Forma Therapeutics shares, roughly 121 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Forma Therapeutics.

Find out more about how you can short Forma Therapeutics stock.

Forma Therapeutics share dividends

We're not expecting Forma Therapeutics to pay a dividend over the next 12 months.

Forma Therapeutics overview

Forma Therapeutics Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts. .

Frequently asked questions

What percentage of Forma Therapeutics is owned by insiders or institutions?
Currently 7.734% of Forma Therapeutics shares are held by insiders and 91.671% by institutions. How many people work for Forma Therapeutics?
Latest data suggests 139 work at Forma Therapeutics. When does the fiscal year end for Forma Therapeutics?
Forma Therapeutics's fiscal year ends in December. Where is Forma Therapeutics based?
Forma Therapeutics's address is: 500 Arsenal Street, Watertown, MA, United States, 02472 What is Forma Therapeutics's ISIN number?
Forma Therapeutics's international securities identification number is: US34633R1041